OrbiMed’s AbbVie ABBV Stock Holding History

OrbiMed’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-100,000	Closed	-$9.82M	–	144
2020 Q2	$9.82M	Buy	+100,000	New	+$8.8M	0.14%	100
2019 Q3	–	Sell	-200,000	Closed	-$14.5M	–	118
2019 Q2	$14.5M	Buy	+200,000	New	+$15.7M	0.23%	81
2015 Q3	–	Sell	-300,000	Closed	-$20.2M	–	133
2015 Q2	$20.2M	Buy	+300,000	New	+$19.6M	0.17%	84
2014 Q2	–	Sell	-250,000	Closed	-$12.8M	–	133
2014 Q1	$12.8M	Hold	250,000	–	–	0.16%	78
2013 Q4	$13.2M	Hold	250,000	–	–	0.19%	75
2013 Q3	$11.2M	Buy	+250,000	New	+$11.1M	0.2%	74

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OrbiMed's ABBV Position: Q4 2023 in Review

OrbiMed sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 330,000 shares — an estimated $49.2M sold.

OrbiMed first reported a position in ABBV in Q2 2013 and held it in 32 quarters. The position peaked at $448M in Q2 2015. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

OrbiMed reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 330,000 AbbVie shares in Q4 2023, an estimated $49.2M.
OrbiMed first reported a position in AbbVie in Q2 2013 and held it in 32 quarters.
OrbiMed's AbbVie position peaked at $448M in Q2 2015.
3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.